Correct me if I'm wrong, but that's what I'm gathering from this report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996517/pdf/medicina-57-00199.pdf"As was also noted in the BMJ Opinion, pfιzєr/BioNTech and mσdernα reported the relative
risk reduction of their ναccιnєs, but the manufacturers did not report a corresponding
absolute risk reduction, which “appears to be less than 1%” [9]."
The FDA’s advice for
information providers includes:
“Provide absolute risks, not just relative risks. Patients are unduly influenced
when risk information is presented using a relative risk approach; this can result
in suboptimal decisions. Thus, an absolute risk format should be used.”
See the chart on page 5!